Tag: stock options

TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- FirstService Corporation (TSX and NASDAQ: FSV) (“FirstService”) announced today that, further to its previously announced acceptance by the Toronto Stock Exchange (the “TSX”) of a notice filed by FirstService of its intention to make a normal course issuer bid (the “NCIB”) with respect to its outstanding common shares, it has received approval from the TSX to amend the NCIB (the “Amended NCIB”), effective on June 4, 2026. The Amended NCIB will increase the maximum number of common shares that may be repurchased from 1,600,000, representing 3.9% of the “public float” of common shares as of August 12, 2025, to 4,118,199, representing 10% of the “public float” of common shares as of August 12, 2025, the maximum amount allowable under the rules of the TSX. No other terms of the NCIB have been amended. Under the NCIB, as of May 31, 2026, FirstService has repurchased for cancellation an aggregate of 931,182 common shares at an average price of US$132.38 per share (or a total of US$123.3 million).

BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares of Vor Bio’s common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).        

REGISTRATION OF THE COMBINATION OF SHARES OF DIGITALIST GROUP PLC, AND ADJUSTMENT OF THE MAXIMUM NUMBERS OF SHARES IN THE COMPANY AVAILABLE FOR SUBSCRIPTION UNDER THE COMPANY’S CONVERTIBLE LOAN INSTRUMENTS AND THE 2021 STOCK OPTION PROGRAM, AS WELL AS THE SUBSCRIPTION PRICES

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment.

Increases 2025 Adjusted EBITDA Guidance